Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on April 23, 2025. The company is headquartered in Bothell, WA, and its common stock trades on The Nasdaq Capital Market.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose a regulatory communication event.
Material Changes
No material financial changes or operational updates are reported in this filing. The report discloses that the Company conducted a presentation to members of the investment community on April 23, 2025.
Guidance, Outlook, and Risks
The filing references a corporate presentation (Exhibit 99.1) furnished to the investment community. However, the text of the presentation is not included in this filing. The Company explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under the Exchange Act and is not subject to the liabilities of Section 18. Consequently, no specific guidance, outlook, risks, or contingencies are detailed within the body of this 8-K.
Key Facts for Investor Verification
- Verify the content of the corporate presentation (Exhibit 99.1) separately, as it is not embedded in the text of this filing.
- Note that the presentation materials are not legally "filed" and do not carry the same liability protections as standard SEC filings.
- Confirm the date of the investor presentation was April 23, 2025.
- Review the company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains none.